- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04798508
EXPRE-SON-REA : Expressive Own Names in Neurophysiologic Assessment of Comatose Patients (EXPRESONREA)
EXPRE-SON-REA : Expressive Versus Neutral Own Names in Neurophysiologic Prognosis Assessment of Intensive Care Unit Comatose Patients.
Evaluating the neurologic prognosis in disorders of consciousness (DOC) patients is still a crucial issue in intensive care units.
Neurophysiology allows the investigators to record cerebral responses of patients to auditory stimuli and in particularly to their own name. Numerous studies try to improve the relevance of the auditory stimuli used in this paradigm.
Here the investigators assess if the use of own name stimuli uttered by more expressive voices (for example smiling voices) modulates the cerebral responses recorded. They then correlate these cerebral responses to the neurologic prognosis at three months.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Late auditory evoked potentials (as P3 wave) are used in neurophysiology to assess the level of consciousness in DOC (disorder of consciousness) patients. The P3 wave, elicited by listening standard and deviant stimuli, corresponds to the activation of a frontoparietal network and is considered to reflect a cognitive attention task. Using the own name of the patient as deviant stimuli improve the ability to detect the P3 wave because of the particularly relevance of this stimulus for the patient. However the correlation of this P3 wave and neurologic prognosis is still imperfect and depends on the etiology of the DOC.
In human cognition, to identify the expressivity valence of a voice is essential. Neural processing of expressive voices involves more widespread brain areas than neutral voices processing.
Here the investigators assume that using own name stimuli uttered by more expressive voices (positive : smiling voice or negative : rough voice) should recruit more widespread brain areas and modulate the cerebral responses recorded. The investigators then evaluate if these cerebral responses are relevant markers of consciousness and correlate them to neurologic prognosis at three months.
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Estelle Pruvost-Robieux, MD
- Número de telefone: + 33 1 45 65 81 89
- E-mail: e.pruvost@ghu-paris.fr
Estude backup de contato
- Nome: Martine Gavaret, Professor
- Número de telefone: + 33 1 45 65 81 89
- E-mail: m.gavaret@ghu-paris.fr
Locais de estudo
-
-
-
Paris, França, 75014
- Recrutamento
- GHU Paris Psychiatrie Neurosciences
-
Contato:
- Estelle Pruvost-Robieux, MD
- Número de telefone: +33 1 45 65 81 89
- E-mail: e.pruvost@ghu-paris.fr
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age over 18
- Disorder of consciousness defined as :
Glasgow coma scale < 8 or >8 but
- eyes opening to pain only
- No response to basic command
- Available neuro-imagery (CT-scan or MRI)
- Normal temperature (no fever or hypothermia)
- Normal blood pressure during neurophysiologic evaluation
- Given consent from relatives
Exclusion Criteria:
- Brain death
- Known deafness
- Severe sepsis uncontrolled during neurophysiologic evaluation
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: N / D
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Outro: Whole group
The whole group listen successively the 3 paradigms :
|
Evoked related potential are performed for each patient during listen to its own name uttered by i) a neutral voice ii) a smiling voice iii) a rough voice
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Positive predictive values of P3a responses to own-names uttered by expressive voices (smiling and rough voices) and neutral voices for the neuroprognosis at 3 months
Prazo: 3 months from DOC evaluation
|
Determination of the positive predictive values of the occurence of the P3a wave recorded with expressive and neutral voices for neuroprognostic assessment at 3 months (according to the GOS-E scale)
|
3 months from DOC evaluation
|
Negative predictive values of P3a responses to own-names uttered by expressive voices (smiling and rough voices) and neutral voices at 3 months for the neuroprognosis at 3 months
Prazo: 3 months from DOC evaluation
|
Determination of the negative predictive values of the occurence of the P3a wave recorded with expressive and neutral voices for neuroprognostic assessment at 3 months (according to the GOS-E scale)
|
3 months from DOC evaluation
|
Sensitivity of P3a responses occurences to own-names uttered by expressive voices (smiling and rough voices) and neutral voices at 3 months for the neuroprognosis at 3 months
Prazo: 3 months from DOC evaluation
|
Determination of the sensibility of the occurence of the P3a wave recorded with expressive and neutral voices for neuroprognostic assessment at 3 months (according to the GOS-E scale)
|
3 months from DOC evaluation
|
Specificity of P3a responses to own-names uttered by expressive voices (smiling and rough voices) and neutral voices at 3 months for the neuroprognosis at 3 months
Prazo: 3 months from DOC evaluation
|
Determination of the specificity of the occurence of the P3a wave recorded with expressive and neutral voices for neuroprognostic assessment at 3 months (according to the GOS-E scale)
|
3 months from DOC evaluation
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Negative predictive value of P3a to own-name uttered by expressive voices and neutral voices according to the CRS-r scale
Prazo: 7, 14 and 28 days from DOC evaluation
|
Determination of the negative predictive value of P3a waves (present or absent) for neuroprognostic at 7 days, 14 days and 28 days (according to the CRS-r scale)
|
7, 14 and 28 days from DOC evaluation
|
Positive predictive value of P3a to own-name uttered by expressive voices and neutral voices according to the CRS-r scale
Prazo: 7, 14 and 28 days from DOC evaluation
|
Determination of the positive predictive value of P3a waves (present or absent) for neuroprognostic at 7 days, 14 days and 28 days (according to the CRS-r scale)
|
7, 14 and 28 days from DOC evaluation
|
Sensitivity of P3a responses occurences uttered by expressive voices and neutral voices according to the CRS-r scale
Prazo: 7, 14 and 28 days from DOC evaluation
|
Determination of the sensibility of P3a waves (present or absent) for neuroprognostic at 7 days, 14 days and 28 days (according to the CRS-r scale)
|
7, 14 and 28 days from DOC evaluation
|
Specificity of P3a to own-name uttered by expressive voices and neutral voices according to the CRS-r scale
Prazo: 7, 14 and 28 days from DOC evaluation
|
Determination of the specificity of P3a waves (present or absent) for neuroprognostic at 7 days, 14 days and 28 days (according to the CRS-r scale)
|
7, 14 and 28 days from DOC evaluation
|
Negative predictive value of P3a to own-name uttered by expressive voices and neutral voices according to eyes-opening
Prazo: 3 months
|
Determination of the negative predictive value of P3a waves (present or absent) for eyes-opening at 3 months
|
3 months
|
Positive predictive value of P3a to own-name uttered by expressive voices and neutral voices according to eyes-opening
Prazo: 3 months
|
Determination of the positive predictive value of P3a waves (present or absent) for eyes-opening at 3 months
|
3 months
|
Sensitivity of P3a responses occurences uttered by expressive voices and neutral voices according to eyes-opening
Prazo: 3 months
|
Determination of the sensibility of P3a waves (present or absent) for eyes-opening at 3 months
|
3 months
|
Specificity of P3a to own-name uttered by expressive voices and neutral voices according to eyes-opening
Prazo: 3 months
|
Determination of the specificity of P3a waves (present or absent) for eyes-opening at 3 months
|
3 months
|
Description of the amplitudes of the P3a wave to own-name uttered by expressive voices versus neutral voices.
Prazo: 3 months
|
Amplitudes of P3a waves recorded with own name uttered by expressive and neutral voices
|
3 months
|
Description of the latencies of the P3a wave to own-name uttered by expressive voices versus neutral voices.
Prazo: 3 months
|
Latencies of P3a waves recorded with own name uttered by expressive and neutral voices
|
3 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2020-A00747-32
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .